About Us

About Luxembourg Bio Technologies

At Luxembourg Bio Technologies, we specialize in providing products to address your peptide synthesis needs. Many of our coupling reagents, especially our proprietary products, are designed to provide maximum yield with minimal racemization. We are here to help you, whether you are using Boc, CBZ , PNZ or Fmoc chemistry, and  solid-phase or solution-phase peptide synthesis.

Luxembourg Bio Technologies believes in using green chemistry and sustainable methods whenever possible, and many of our products are designed to be compatible with environmental friendly conditions. We work under the most rigorous quality assurance standards available to provide you with the best possible quality products, such as COMU, HDMC, OxymaPure, DEPBT, EDC.HCL, and many others. Our products are being applied in a wide range of areas, including peptide, oligonucleotide, and nanoparticle synthesis.

 Luxembourg Bio Technologies patented IP materials will provide you with every advantage when facing the needs of an ever-growing pharmaceutical industry, and our sustainable production methods ensure safer products with a smaller ecological footprint.

Let us help you create solutions for your next product in peptide synthesis, and escort your ongoing projects with our well-known products.

Company Background

The main goal of Luxembourg Bio Technologies is to step forward, bringing innovation and development to the market. Luxembourg’s philosophy is to follow the market’s needs and implement outcomes of intensive research, development, and innovation. We pay special attention to the economy and environmental demands to achieve optimal solutions. As a modern industrial operative should, we strive to preserve and protect the environment and to consider the outcomes of our industrial field, in order to make a more efficient, safe, worthwhile and eco-friendly industry for generations to come.

News

Budapest, Hungary, July 26th: Ethyl (hydroxyimino)cyanoacetate, OxymaPureTM CAS No. 3849-21-6, has been registered for REACH at ECHA

OxymaPureTM, CAS No. 3849-21-6, brand of Luxembourg Bio Technlogies has been registered by our Hungarian CMO, Első Vegyi Industria, for REACH at ECHA as part of the regulation of the European Union.
This regulation adopted to improve the protection of human health and environment from the risks that can be posed by chemicals.
Other product such as DIC CAS No. 693-13-0 and EDC.HCl CAS No. 25952-53-8 are in process of registration for REACH at ECHA.

Uppsala, Sweden, 25 April 2017: Gyros Protein Technologies signs distribution agreement with Luxembourg Bio Technologies for peptide synthesis reagents.

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has signed an exclusive distribution agreement with Luxembourg Bio Technologies for three of its proprietary coupling agents, PyOxim® and K-Oxyma®, and HDMC on a non-exclusive basis. Gyros Protein Technologies will sell these reagents as part of its PurePep™ brand. As part of the agreement, Gyros Protein Technologies has exclusively distribution for the north America market for orders below 35 kg per product.

Yoav Luxembourg, CEO of Luxembourg Bio Technologies, said: “We are pleased to have Gyros Protein Technologies as our partner, and our distribution agreement represents an important step to enable more researchers to have access to the highest quality coupling agents designed to provide maximum yield with minimal racemization.”

Jasmine Gruia-Gray, VP Marketing, Gyros Protein Technologies, commented: “Gyros Protein Technologies takes pride in providing high quality peptide synthesis reagents and platforms. At the core of Gyros Protein Technologies’ PurePep product brand is purity, trust and ingenuity in peptide synthesis, supporting the Company’s pure reliability solution strategy – synthesizers, software and reagents, which are in turn underpinned by our decades-long track record of providing customers with outstanding service and support. We are pleased to partner with Luxembourg Bio Technologies, given their strong market position as a provider of high quality and innovative peptide synthesis reagents.”

Mr. Abraham Luxembourg (1927-2012)

Milestones

Luxembourg Bio Technologies Ltd., a family-owned and managed company, was founded in 2008 by our President and CEO, Mr. Yoav Luxembourg.

Luxembourg Bio Technologies (LBT) was a spinoff of Luxembourg Industries Ltd, which was established in 1962 by Mr. Abraham Luxembourg (1927-2012) – father and mentor of Mr. Yoav Luxembourg.

The spin off became a necessity as the biotechnology activity had grown to such an extent that it could not remain one of the departments of Luxembourg Industries. It was essential to separate the chemical industry and the biotech industry. Inevitably, in 2008, Luxembourg Bio Technologies was formed.

Our company’s guiding philosophy has always been that by combining scientific innovation with environmental awareness. We have to provide optimal solutions for any peptide synthesis, amide and ester bond formation. As such, our goal is to bring the most current developments in coupling reagents, racemization suppressors, and protecting groups to market.
We hope that our work will make the world of peptide chemistry one that is more efficient, safe, and eco-friendly.

At Luxembourg Bio Technologies, we apply our extensive knowledge to each customer’s unique needs. We are committed to producing the highest quality molecules while constantly searching for the most efficient, environmental friendly and innovative new materials to meet the industry’s needs.
Our sustainable methods of production create a safer environment and cleaner materials while leaving either no or a smaller ecological footprint, if any.

All synthetic and analytical methods employed in our facilities are held to the highest international standards. We develop and manufacture our materials using contract manufacturing organizations located mainely in Europe and REACH-ECHA regulations. A sample of each batch we produce is saved for seven years to allow continuous testing and analysis of all our products.

More About Us

Test Case

Peptide-bond formation is a key process in the synthesis of peptide oligomers. Among the many coupling and protecting agents techniques reported, carbodiimides combine strong acylation potency and smooth reaction conditions and are commonly used in the presence of additives. Recently, ethyl 2-cyano-2-(hydroxyimino)acetate (OxymaPure) has emerged as a highly reactive alternative to the classic and explosion-prone benzotriazolic additives, namely 1-hydroxybenzotriazole(HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt) We recently reported a new oxime additive, 5(hydroxyimino)-1,3-dimethylpyrimidine- 2,4,6(1H,3H,5H)-trione (Oxyma-B). This new additive showed satisfactory solubility in various solvents (DMF, ACN, and THF). It was also more effective controlling optical purity during the synthesis of Z-Phg-Pro-NH2, Z-Phe-Val-Pro-NH2, H-Gly-Ser-Phe-NH2, H-Gly-Cys-Phe-NH2, H-Gly-Cys(Acm)-Phe-NH2 and H-Gly-His-Phe-NHwhen compared to related Oxyma- and benzotriazole-based reagents. Oxyma-B also proved to be advantageous compared to the related HONM, because the latter cannot be used with carbodiimides. Furthermore, Oxyma-B showed satisfactory performance in assembling demanding sequences such as the Aib-enkephalinpentapeptide (H-Tyr-Aib-Aib-Phe-Leu-NH2).

Swift Sourcing of Rare Materials

Using our strong global connections and log-term relationships with producers and suppliers, we will search the Earth to obtain the materials you need.

Pilot and Scale-Up Projects

Looking to launch a new pilot project but don’t have a manufacturing plant of your own? Created a project in your lab but lack the facilities to scale it up? Luxembourg Bio Technologies collaborates with facilities in Europe on projects ranging from laboratory-scale experiments to multi-liter reactions. Let us know your exact needs and we’ll be happy to put your project in motion. All projects will be kept confidential under a non-disclosure agreement.

Point of View

Key projects in the fine chemicals sector, especially those serving the pharmaceutical industry, must always be on the lookout for the ‘undesirable result’. This can be the break-even point from which a project can fly sky-high or fall to the bottom of the pit.

Read more